NR 603 – CEA Respiratory Questions
with Answers and Rationales
SECTION I: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
(Questions 1–20)
1. According to the GOLD 2025 guidelines, which of the following is the
diagnostic criterion for airflow obstruction in COPD?
A. FEV1/FVC ratio < 0.70 post-bronchodilator
B. FEV1 < 80% predicted
C. FVC < 80% predicted
D. FEV1/FVC ratio < 0.80 post-bronchodilator
Rationale: The GOLD 2025 guidelines continue to define airflow obstruction as a
post-bronchodilator FEV1/FVC ratio < 0.70. This criterion confirms the presence
of persistent airflow limitation characteristic of COPD.
2. A 65-year-old patient with a 40-pack-year smoking history presents with
progressive dyspnea, chronic cough, and sputum production. Which
diagnostic test is essential to confirm the diagnosis of COPD?
A. Chest X-ray
B. Spirometry
C. Arterial blood gas
D. Complete blood count
Rationale: Spirometry is essential for confirming the diagnosis of COPD. It
demonstrates persistent airflow limitation with a post-bronchodilator FEV1/FVC
ratio < 0.70. Chest X-ray and other tests may support the diagnosis but are not
diagnostic.
3. A patient with COPD is classified as GOLD Group E. Which of the
following best describes this classification?
,A. Low symptoms, low exacerbation risk
B. Low symptoms, high exacerbation risk
C. High symptoms, low exacerbation risk
D. High symptoms, high exacerbation risk
Rationale: GOLD Group E represents patients with high symptom burden (CAT ≥
10 or mMRC ≥ 2) and high exacerbation risk (≥ 2 moderate exacerbations or ≥ 1
hospitalization in the past year).
4. Which of the following is the most critical intervention for a patient newly
diagnosed with COPD?
A. Initiating inhaled corticosteroids
B. Prescribing long-acting bronchodilators
C. Smoking cessation
D. Starting pulmonary rehabilitation
Rationale: Smoking cessation is the most critical intervention for patients with
COPD. It slows disease progression, reduces symptom burden, and improves
survival. All other interventions are adjunctive.
5. A patient with COPD and frequent exacerbations is started on triple
therapy. Which of the following comprises triple therapy for COPD?
A. LABA + LAMA + Theophylline
B. LABA + LAMA + ICS
C. SABA + SAMA + ICS
D. LABA + ICS + Oral corticosteroid
Rationale: Triple therapy for COPD consists of a long-acting beta-agonist
(LABA), long-acting muscarinic antagonist (LAMA), and inhaled corticosteroid
(ICS). This combination is recommended for patients with frequent exacerbations.
6. A patient with COPD has an FEV1 of 55% predicted, mMRC score of 3,
and experienced one hospitalization for exacerbation in the past year.
According to GOLD 2025, this patient should be classified as:
,A. GOLD Group A
B. GOLD Group B
C. GOLD Group C
D. GOLD Group E
Rationale: GOLD Group E includes patients with high symptom burden (mMRC
≥ 2) and high exacerbation risk (≥ 2 exacerbations or ≥ 1 hospitalization). This
patient has both high symptoms and high exacerbation risk.
7. Which medication class is the preferred initial bronchodilator for a patient
with COPD GOLD Group B?
A. Inhaled corticosteroid alone
B. Long-acting bronchodilator (LABA or LAMA)
C. Short-acting bronchodilator alone
D. Triple therapy
Rationale: For GOLD Group B (high symptoms, low exacerbation risk), initial
therapy should be a single long-acting bronchodilator (LABA or LAMA).
8. A patient with COPD develops acute worsening of dyspnea, increased
sputum purulence, and volume. This is best described as:
A. COPD progression
B. Acute exacerbation of COPD
C. Pneumonia
D. Pulmonary embolism
Rationale: An acute exacerbation of COPD is defined as an acute worsening of
respiratory symptoms that results in additional therapy. Classic features include
increased dyspnea, sputum volume, and sputum purulence.
9. Which of the following is a risk factor for poor outcomes in COPD
exacerbations?
A. Young age
B. Female gender
, C. Frequent exacerbations in the past year
D. Absence of comorbidities
Rationale: Frequent exacerbations in the past year are a significant risk factor for
poor outcomes. They indicate disease progression and increased mortality risk.
10. A patient with COPD and chronic hypoxemia (PaO2 ≤ 55 mmHg) should
be prescribed:
A. Inhaled corticosteroids
B. Long-term oxygen therapy
C. Theophylline
D. Mucolytics
Rationale: Long-term oxygen therapy is indicated for patients with COPD who
have chronic resting hypoxemia (PaO2 ≤ 55 mmHg or SpO2 ≤ 88%). It improves
survival in these patients.
11. Which of the following is a contraindication to home oxygen therapy in a
patient with COPD?
A. PaO2 of 52 mmHg
B. Cor pulmonale
C. Active smoking
D. Oxygen saturation of 89%
Rationale: Active smoking is a contraindication to home oxygen therapy due to
the fire risk and the potential for oxygen to suppress the respiratory drive in
patients with CO2 retention.
12. A patient with COPD is started on tiotropium. This medication works by:
A. Stimulating beta-2 receptors
B. Blocking muscarinic receptors
C. Reducing airway inflammation
D. Inhibiting phosphodiesterase
with Answers and Rationales
SECTION I: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
(Questions 1–20)
1. According to the GOLD 2025 guidelines, which of the following is the
diagnostic criterion for airflow obstruction in COPD?
A. FEV1/FVC ratio < 0.70 post-bronchodilator
B. FEV1 < 80% predicted
C. FVC < 80% predicted
D. FEV1/FVC ratio < 0.80 post-bronchodilator
Rationale: The GOLD 2025 guidelines continue to define airflow obstruction as a
post-bronchodilator FEV1/FVC ratio < 0.70. This criterion confirms the presence
of persistent airflow limitation characteristic of COPD.
2. A 65-year-old patient with a 40-pack-year smoking history presents with
progressive dyspnea, chronic cough, and sputum production. Which
diagnostic test is essential to confirm the diagnosis of COPD?
A. Chest X-ray
B. Spirometry
C. Arterial blood gas
D. Complete blood count
Rationale: Spirometry is essential for confirming the diagnosis of COPD. It
demonstrates persistent airflow limitation with a post-bronchodilator FEV1/FVC
ratio < 0.70. Chest X-ray and other tests may support the diagnosis but are not
diagnostic.
3. A patient with COPD is classified as GOLD Group E. Which of the
following best describes this classification?
,A. Low symptoms, low exacerbation risk
B. Low symptoms, high exacerbation risk
C. High symptoms, low exacerbation risk
D. High symptoms, high exacerbation risk
Rationale: GOLD Group E represents patients with high symptom burden (CAT ≥
10 or mMRC ≥ 2) and high exacerbation risk (≥ 2 moderate exacerbations or ≥ 1
hospitalization in the past year).
4. Which of the following is the most critical intervention for a patient newly
diagnosed with COPD?
A. Initiating inhaled corticosteroids
B. Prescribing long-acting bronchodilators
C. Smoking cessation
D. Starting pulmonary rehabilitation
Rationale: Smoking cessation is the most critical intervention for patients with
COPD. It slows disease progression, reduces symptom burden, and improves
survival. All other interventions are adjunctive.
5. A patient with COPD and frequent exacerbations is started on triple
therapy. Which of the following comprises triple therapy for COPD?
A. LABA + LAMA + Theophylline
B. LABA + LAMA + ICS
C. SABA + SAMA + ICS
D. LABA + ICS + Oral corticosteroid
Rationale: Triple therapy for COPD consists of a long-acting beta-agonist
(LABA), long-acting muscarinic antagonist (LAMA), and inhaled corticosteroid
(ICS). This combination is recommended for patients with frequent exacerbations.
6. A patient with COPD has an FEV1 of 55% predicted, mMRC score of 3,
and experienced one hospitalization for exacerbation in the past year.
According to GOLD 2025, this patient should be classified as:
,A. GOLD Group A
B. GOLD Group B
C. GOLD Group C
D. GOLD Group E
Rationale: GOLD Group E includes patients with high symptom burden (mMRC
≥ 2) and high exacerbation risk (≥ 2 exacerbations or ≥ 1 hospitalization). This
patient has both high symptoms and high exacerbation risk.
7. Which medication class is the preferred initial bronchodilator for a patient
with COPD GOLD Group B?
A. Inhaled corticosteroid alone
B. Long-acting bronchodilator (LABA or LAMA)
C. Short-acting bronchodilator alone
D. Triple therapy
Rationale: For GOLD Group B (high symptoms, low exacerbation risk), initial
therapy should be a single long-acting bronchodilator (LABA or LAMA).
8. A patient with COPD develops acute worsening of dyspnea, increased
sputum purulence, and volume. This is best described as:
A. COPD progression
B. Acute exacerbation of COPD
C. Pneumonia
D. Pulmonary embolism
Rationale: An acute exacerbation of COPD is defined as an acute worsening of
respiratory symptoms that results in additional therapy. Classic features include
increased dyspnea, sputum volume, and sputum purulence.
9. Which of the following is a risk factor for poor outcomes in COPD
exacerbations?
A. Young age
B. Female gender
, C. Frequent exacerbations in the past year
D. Absence of comorbidities
Rationale: Frequent exacerbations in the past year are a significant risk factor for
poor outcomes. They indicate disease progression and increased mortality risk.
10. A patient with COPD and chronic hypoxemia (PaO2 ≤ 55 mmHg) should
be prescribed:
A. Inhaled corticosteroids
B. Long-term oxygen therapy
C. Theophylline
D. Mucolytics
Rationale: Long-term oxygen therapy is indicated for patients with COPD who
have chronic resting hypoxemia (PaO2 ≤ 55 mmHg or SpO2 ≤ 88%). It improves
survival in these patients.
11. Which of the following is a contraindication to home oxygen therapy in a
patient with COPD?
A. PaO2 of 52 mmHg
B. Cor pulmonale
C. Active smoking
D. Oxygen saturation of 89%
Rationale: Active smoking is a contraindication to home oxygen therapy due to
the fire risk and the potential for oxygen to suppress the respiratory drive in
patients with CO2 retention.
12. A patient with COPD is started on tiotropium. This medication works by:
A. Stimulating beta-2 receptors
B. Blocking muscarinic receptors
C. Reducing airway inflammation
D. Inhibiting phosphodiesterase
